The efficacy on dysuria and safety of combination therapy with terazosin and bethanechol in Benign Prostatic Hyperplasia patients with Underactive Bladder
- Conditions
- Diseases of the genitourinary system
- Registration Number
- KCT0005772
- Lead Sponsor
- ational Health Insurance Service Ilsan Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Terminated
- Sex
- Male
- Target Recruitment
- 123
(1) Patients over 19 years diagnosed with benign prostatic hyperplasia
(2) Those with an IPSS total score of 8 or more and a maximum urine velocity of 15mL/s or less
(3) Those with BVE(Bladder Void Efficiency)<90
*BVE=(Voided Volume/(Voided Volume+Post Voided Residual)*100)
(4) Those who voluntarily decide to participate in this study and consent in writing to the subject's consent.
(1) Patients with urinary tract stones, urethral stenosis or urinary tract infection
(2) Prostate cancer patients or patients who have undergone prostate surgery
(3) Patients who have undergone surgery due to bladder muscle obstruction or prostatic hyperplasia
(4) Patients diagnosed with cardiovascular disease, liver disease, orthostatic hypotension, hypertension or renal dysfunction
(5) Patients taking anticholinergic drugs, beta3-antagonists, and 5-alpha reductase inhibitors.
(6) Patients with malignant tumors in the urinary tract epithelium
(7) Those with hypersensitivity to alpha-blocker agents or cholinergic agents
(8) Those with a histoory of urinary tract related surgery
(9) Patients with mechanical obstruction of the gastrointestinal tract or urinary tract
(10) Convulsive gastrointestinal disease, gastric ulcer, acute gastrointestinal inflammatory disease
(11) peritonitis patients
(12) Vagus hypertonia patients
(13) Asthma patients
(14) Patients with hyperthyroidism
(15) Patients with coronary artery obstruction
(16) Patients with bradycardia, atrioventricular conduction disorder, and vasomotor instability
(17) Patients with epilepsy and Parkinsonism
(18) Patients who did not heal after undergoing gastric duct anastomosis
(19) Others who are inadequate to participate in this research when judged by the research director or the research manager
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Internation Prostate Symptom Score(IPSS) total change
- Secondary Outcome Measures
Name Time Method Maximum urine velocity(Qmax) change;Post-Void Residual urine(PVR) change;Internation Prostate Symptom Score-QoL(IPSS-QoL) change